Cargando…

Breast cancer in women aged 75 years and older – tumour characteristics and treatment options

INTRODUCTION: An optimal approach to older women with breast cancer is still a major challenge. In this paper, we present a retrospective analysis of treatment in patients aged 75 years and older who were treated at the Holycross Cancer Centre in 2015–2019. MATERIAL AND METHODS: The analysed group c...

Descripción completa

Detalles Bibliográficos
Autores principales: Kędzierawski, Piotr, Mężyk, Ryszard
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Termedia Publishing House 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8077806/
https://www.ncbi.nlm.nih.gov/pubmed/33935615
http://dx.doi.org/10.5114/pm.2021.104432
_version_ 1783684949012905984
author Kędzierawski, Piotr
Mężyk, Ryszard
author_facet Kędzierawski, Piotr
Mężyk, Ryszard
author_sort Kędzierawski, Piotr
collection PubMed
description INTRODUCTION: An optimal approach to older women with breast cancer is still a major challenge. In this paper, we present a retrospective analysis of treatment in patients aged 75 years and older who were treated at the Holycross Cancer Centre in 2015–2019. MATERIAL AND METHODS: The analysed group consisted of 259 women. For estimation of the general status of patients, we used the Geriatric 8 questionnaire. For every patient, an individual treatment plan was established. Survival analysis was performed; disease-free survival (DFS), cancer-specific survival, and overall survival (OS) were calculated by the Kaplan-Meier method. For DFS and OS, the Cox proportional-hazard regression was applied. RESULTS: The mean age in the analysed group was 80 years. Stage I and II cancer accounted for over 80% of patients. Radical mastectomy was performed in 56% and breast-conserving surgery in over 34% of patients. Sentinel lymph node biopsy was used in 114 patients. Preoperative systemic treatment was applied in 34 and postoperative chemotherapy in 51 patients, respectively. Trastuzumab was used in 23 patients. Postoperative hormonal therapy was applied in 205 and radiotherapy in 178 patients. During the observation after the treatment 32 patients died, while 227 survived. In multivariate analysis for DFS hormonotherapy was statistically significant for OS clinical stage and hormonotherapy. CONCLUSIONS: The treatment plan for older women consisted of surgery and radiation therapy, and systemic treatment should be always considered. The decision should be made by the breast cancer team.
format Online
Article
Text
id pubmed-8077806
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Termedia Publishing House
record_format MEDLINE/PubMed
spelling pubmed-80778062021-04-29 Breast cancer in women aged 75 years and older – tumour characteristics and treatment options Kędzierawski, Piotr Mężyk, Ryszard Prz Menopauzalny Original Paper INTRODUCTION: An optimal approach to older women with breast cancer is still a major challenge. In this paper, we present a retrospective analysis of treatment in patients aged 75 years and older who were treated at the Holycross Cancer Centre in 2015–2019. MATERIAL AND METHODS: The analysed group consisted of 259 women. For estimation of the general status of patients, we used the Geriatric 8 questionnaire. For every patient, an individual treatment plan was established. Survival analysis was performed; disease-free survival (DFS), cancer-specific survival, and overall survival (OS) were calculated by the Kaplan-Meier method. For DFS and OS, the Cox proportional-hazard regression was applied. RESULTS: The mean age in the analysed group was 80 years. Stage I and II cancer accounted for over 80% of patients. Radical mastectomy was performed in 56% and breast-conserving surgery in over 34% of patients. Sentinel lymph node biopsy was used in 114 patients. Preoperative systemic treatment was applied in 34 and postoperative chemotherapy in 51 patients, respectively. Trastuzumab was used in 23 patients. Postoperative hormonal therapy was applied in 205 and radiotherapy in 178 patients. During the observation after the treatment 32 patients died, while 227 survived. In multivariate analysis for DFS hormonotherapy was statistically significant for OS clinical stage and hormonotherapy. CONCLUSIONS: The treatment plan for older women consisted of surgery and radiation therapy, and systemic treatment should be always considered. The decision should be made by the breast cancer team. Termedia Publishing House 2021-03-15 2021-04 /pmc/articles/PMC8077806/ /pubmed/33935615 http://dx.doi.org/10.5114/pm.2021.104432 Text en Copyright © 2021 Termedia https://creativecommons.org/licenses/by-nc-sa/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0). License (http://creativecommons.org/licenses/by-nc-sa/4.0/ (https://creativecommons.org/licenses/by-nc-sa/4.0/) )
spellingShingle Original Paper
Kędzierawski, Piotr
Mężyk, Ryszard
Breast cancer in women aged 75 years and older – tumour characteristics and treatment options
title Breast cancer in women aged 75 years and older – tumour characteristics and treatment options
title_full Breast cancer in women aged 75 years and older – tumour characteristics and treatment options
title_fullStr Breast cancer in women aged 75 years and older – tumour characteristics and treatment options
title_full_unstemmed Breast cancer in women aged 75 years and older – tumour characteristics and treatment options
title_short Breast cancer in women aged 75 years and older – tumour characteristics and treatment options
title_sort breast cancer in women aged 75 years and older – tumour characteristics and treatment options
topic Original Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8077806/
https://www.ncbi.nlm.nih.gov/pubmed/33935615
http://dx.doi.org/10.5114/pm.2021.104432
work_keys_str_mv AT kedzierawskipiotr breastcancerinwomenaged75yearsandoldertumourcharacteristicsandtreatmentoptions
AT mezykryszard breastcancerinwomenaged75yearsandoldertumourcharacteristicsandtreatmentoptions